Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

UK oncologists and cardiologists collaborate to prevent chemo-induced cardiomyopathy in cancer patients

Ever since she was 12 years old, Barbie Johnson has been a Kentucky girl at heart. Raised in the bluegrass, Barbie has worked at UK HealthCare for 18 years, first in gynecologic oncology and now in surgery scheduling.

26 Jan 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.

20 Jan 2023

Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

20 Jan 2023

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

5 Jan 2023

New method combines injectable radioactive gel with systemic chemotherapy to treat pancreatic cancer

Pancreatic cancer is one of the deadliest types of cancer - in the U.S., it is estimated that over 88 percent of people will die from the disease within five years of their diagnosis.

20 Dec 2022

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

Triple-negative breast cancer (TNBC) tumors gain immunosuppression and chemoresistance through interactions between interleukin 34 and myeloid-derived suppressor cells, researchers find.

1 Nov 2022

Duke biomedical engineers develop a two-pronged approach to treating pancreatic cancer

Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models.

21 Oct 2022

Study estimates the cost-effectiveness of therapeutic alternatives

Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.

14 Sep 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Although antiretroviral therapy has markedly improved survival in people with AIDS-associated Kaposi sarcoma (a type of cancer caused by a virus), the condition is still a life-threatening problem in low- and middle-income countries.

15 Jul 2022

Chemo-immunotherapy combination shows promise against pancreatic cancer

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

6 Jun 2022

Study finds no difference in survival between patients treated with paclitaxel drug-coated devices and non-DCDs

New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.

20 May 2022

Study could provide a new approach to treating metastatic triple negative breast cancer

Research from the University of Michigan Rogel Cancer Center could provide a new approach to treating an aggressive form of breast cancer.

12 May 2022

Study shows superiority of Chocolate Touch device for opening blocked arteries in the leg

Patients treated for a blocked artery in the leg were significantly more likely to have an open artery without further interventions at 12 months if they received the second-generation paclitaxel-coated balloon catheter known as the Chocolate Touch device compared with those receiving the commercially-available Lutonix drug-coated balloon catheter, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

The findings of a new study suggest that a ketogenic diet - which is low in carbohydrates and protein, but high in fat - helps to kill pancreatic cancer cells when combined with a triple-drug therapy developed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

22 Mar 2022

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

12 Feb 2022

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (CAS) recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021